We revealed the role of HHLA2 expression as a stimulatory and inhibitory immune checkpoint in colorectal cancer, highlighting that the HHLA2–KIR3DL3/TMIGD2 pathway may contribute to the promising strategy of colorectal cancer treatment. This evidence concerns the gene KIR3DL3 and colorectal cancer.